ArticleFrontiers in pharmacology2024

Cost-effectiveness analysis of first-line sintilimab plus chemotherapy vs. chemotherapy alone for unresectable advanced or metastatic gastric or gastroesophageal junction cancer in China.

Zuojuan Xiang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.